📚 Lecture Overview
This lecture covers Enteroviruses, a major group of naked, positive-strand RNA viruses belonging to the Picornaviridae family. While these viruses primarily replicate in the gastrointestinal tract without causing significant local disease, systemic dissemination can lead to severe conditions ranging from poliomyelitis and aseptic meningitis to myocarditis and hand-foot-and-mouth disease. Understanding their classification, pathogenesis, distinct clinical manifestations, and vaccination strategies is essential for medical exams.
🎯 Key Concepts & Definitions
- Enteroviruses: A genus of naked, icosahedral, single positive-strand RNA (+ssRNA) viruses within the Picornaviridae family that replicate primarily in the gastrointestinal tract.
- Primary vs. Secondary Viremia: Primary viremia occurs when the virus enters the bloodstream from lymphoid tissue (Peyer's patches); secondary viremia follows replication in target tissues, spreading the virus further.
- Flaccid Paralysis: Loss of muscle tone and strength resulting from the destruction of lower motor neurons in the spinal cord by poliovirus, characterized by a lack of sensory loss.
- Herpangina: A severe, self-limited febrile pharyngitis caused mainly by Group A Coxsackieviruses, presenting with painful vesicles on the pharynx, tonsils, or tongue.
- Pleurodynia (Epidemic Myalgia): A condition caused by Group B Coxsackieviruses marked by sudden onset of fever and severe stabbing chest pain.
- Salk Vaccine (IPV): An inactivated (formalinized) poliovirus vaccine that stimulates humoral IgG antibodies but fails to produce mucosal IgA immunity in the gut.
- Sabin Vaccine (OPV): A live attenuated oral poliovirus vaccine that induces both systemic (IgG/IgM) and mucosal (secretory IgA) immunity, allowing community dissemination of vaccine strains.
📖 Main Content
1. Classification & General Characteristics
Enteroviruses belong to the Picornaviridae family.
- Genomic Structure: Small, naked (non-enveloped), icosahedral viruses containing a single positive-strand genomic RNA (+ssRNA).
- Primary Site of Replication: Gastrointestinal tract (GIT) mucosa and lymphoid tissues (does not cause marked local disease in the GIT).
- Human Enterovirus Groups:
1. Polioviruses: Types 1–3
2. Coxsackieviruses Group A: Types 1–24
3. Coxsackieviruses Group B: Types 1–6
4. ECHO viruses: Types 1–33
5. Enteroviruses: Types 68–116
2. Pathogenesis & Epidemiology
- Spread & Replication Path:
1. Primary replication begins in mucosal and lymphoid tissues of the tonsils and pharynx.
2. Direct extension to the intestine, replicating in Peyer's patches.
3. Primary viremia carries the virus to distant target tissues.
4. Viral replication in target tissues leads to secondary viremia. - Transmission & Immunity:
- Virus is shed in stool before symptoms appear and can persist for up to one month.
- Secretory antibodies (IgA) prevent primary multiplication in mucosal sites.
- Serum antibodies (IgG) prevent viremia and systemic dissemination.
- Determinants of Clinical Outcome: Virus serotype, infectious dose, tissue tropism, portal of entry, patient factors, and pregnancy.
3. Poliovirus
Poliovirus causes poliomyelitis, an acute infection affecting the central nervous system (CNS).
- Antigenic Types: 3 stable antigenic types (1, 2, and 3).
- Incubation Period: 7–14 days.
| Clinical Form | Incubation / Features | Key Clinical Findings |
|---|---|---|
| Inapparent / Mild Disease | Occurs in 90% of cases | Most common form; causes mild fever, malaise, headache, nausea, vomiting, sore throat. |
| Non-paralytic Poliomyelitis | Aseptic meningitis | Minor illness accompanied by neck and back stiffness/pain. Recovery is rapid and complete. |
| Paralytic Poliomyelitis | ~1% of infections | Flaccid paralysis due to lower motor neuron destruction. NO sensory loss. Maximal recovery within 6 months. |
| Progressive Post-Polio Atrophy | Rare; decades after infection | Disuse atrophic muscle changes occurring long after initial recovery. |
4. Coxsackieviruses
Coxsackieviruses are generally more pathogenic than ECHOviruses and are split into two major groups:
- Group A Coxsackieviruses: Tend to infect skin and mucous membranes.
- Group B Coxsackieviruses: Tend to infect the heart, pleura, pancreas, and liver.
- Both groups can cause non-specific febrile illness, rashes, upper respiratory tract infections, and aseptic meningitis.
Key Clinical Syndromes of Coxsackieviruses:
- Herpangina (Group A):
- Severe febrile pharyngitis with sudden fever and sore throat.
- Characterized by vesicles on the pharynx, tonsils, or tongue.
- Common in children; self-limited. - Hand-Foot-and-Mouth Disease (Group A16, EV-A71):
- Oral/pharyngeal ulcerations and a vesicular rash on palms and soles.
- Vesicles heal without crusting. - Acute Hemorrhagic Conjunctivitis (Group A24, EV-E70):
- Highly contagious eye infection marked by conjunctival congestion, vascular dilatation, and edema. - Pleurodynia / Epidemic Myalgia (Group B):
- Sudden onset of fever and stabbing chest pain.
- Preceded by malaise, headache, and anorexia.
- Abdominal pain present in ~50% of cases (frequent chief complaint in children). Relapses are common. - Myocardial & Pericardial Infections (Group B):
- Group B is the most common viral cause of heart disease in humans.
- Symptoms resemble ischemic heart disease (IHD), but with fever. Can be fatal in neonates or cause permanent damage. - Generalized Disease of Infants (Group B):
- Severe, rapidly fatal or fully reversible multi-organ involvement (heart, liver, brain). - Aseptic Meningitis (All Group B, many Group A):
- Reversible inflammation; complete recovery, though transient mild muscle weakness may occur. - Type 1 Diabetes (IDDM):
- Development of insulin-dependent diabetes mellitus is linked to recent Group B infections.
5. Laboratory Diagnosis, Treatment & Prevention
Laboratory Diagnosis:
- Specimens: Stools, pharyngeal swabs, blood, CSF.
- Cell Culture: Isolation in primary monkey or human embryo kidney cells (for Coxsackie and Polio).
- Nucleic Acid Detection: RT-PCR (Reverse Transcription PCR) is highly sensitive and specific.
- Serology: Detection of specific IgM or a fourfold increase in IgG titer between acute and convalescent phases.
- CSF Analysis: Used to evaluate enteroviral aseptic meningitis.
Prevention & Treatment:
- Treatment: No specific antiviral therapy exists. Treatment is purely symptomatic (hydration, analgesics, antipyretics).
- General Prevention: Hand hygiene (soap and water for 20 seconds), disinfecting surfaces, avoiding contact with sick individuals.
6. Polio Vaccines Comparison
| Feature | Formalinized Vaccine (Salk / IPV) | Oral Vaccine (Sabin / OPV) |
|---|---|---|
| Vaccine Type | Inactivated / Killed virus (Formalin treated) | Live Attenuated virus |
| Culture Medium | Monkey kidney cell culture | Monkey kidney or human diploid cells |
| Immunity Induced | Humoral / Serum antibodies (IgG) | Systemic (IgG, IgM) AND local mucosal (secretory IgA) |
| Intestinal Immunity | No mucosal IgA produced in gut | Yes (creates robust gut immunity) |
| Viral Shedding | Virus can still replicate in gut upon exposure | Disseminates attenuated progeny into community |
📊 Visual Learning
Diagram 1: Pathogenesis of Enteroviruses
flowchart TD
A[Mucosal Replication] --> B[Peyers Patches]
B --> C[Primary Viremia]
C --> D[Target Organ Replication]
D --> E[Secondary Viremia]
E --> F[Clinical Disease]
Diagram 2: Human Enterovirus Classification & Clinical Features
mindmap
root("Enteroviruses")
"Polioviruses"
"Lower Motor Neuron Damage"
"Flaccid Paralysis No Sensory Loss"
"Aseptic Meningitis"
"Group A Coxsackie"
"Skin and Mucous Membranes"
"Herpangina"
"Hand Foot Mouth Disease"
"Group B Coxsackie"
"Heart Pleura Pancreas Liver"
"Pleurodynia Chest Pain"
"Myocarditis and Pericarditis"
Diagram 3: Polio Vaccine Immune Response Differences
graph TD
A[Salk IPV Inactivated] --> B[Serum IgG Antibodies]
B --> C[No Gut Secretory IgA]
C --> D[Virus Still Replicates in Gut]
E[Sabin OPV Live Attenuated] --> F[Serum IgG and IgM]
F --> G[Local Secretory IgA in Gut]
G --> H[Blocks Intestinal Viral Replication]
💡 Important Points to Remember
- Picornaviridae Characteristics: Enteroviruses are naked, icosahedral, and possess a +ssRNA genome.
- Pure Motor Involvement: Paralytic poliomyelitis causes lower motor neuron damage resulting in flaccid paralysis WITHOUT sensory loss.
- Asymptomatic Predominance: Approximately 90% of poliovirus infections are subclinical/mild febrile illnesses; clinical paralytic disease occurs in only ~1%.
- Group A vs. Group B Tropism:
- Group A = Skin & Mucous Membranes (Herpangina, Hand-Foot-Mouth).
- Group B = Heart, Pleura, Liver, Pancreas (Pleurodynia, Myocarditis, IDDM).
- Vesicle Healing: Hand-Foot-and-Mouth disease skin vesicles heal without crusting.
- Pleurodynia Presentation: Characterized by sudden stabbing chest pain; children often present with abdominal pain. Relapses are common.
- Viral Myocarditis: Coxsackie Group B is the most common viral cause of human heart disease; symptoms mimic ischemic heart disease (IHD) but include fever.
- Salk vs. Sabin Mucosal Immunity: Salk (IPV) gives serum protection (IgG) but NO mucosal intestinal immunity (IgA). Sabin (OPV) gives secretory IgA, preventing wild virus multiplication in the gut.
- Stool Shedding: Enteroviruses shed in stool before symptoms start and continue shedding for up to 1 month.
⚠️ Common Exam Questions & Traps
MCQ & Short Answer Traps:
- Sensory Deficits in Polio:
- Trap: Examiners will describe a patient with paralysis and ask if sensory loss is present.
- Fact: Paralytic polio affects motor neurons only. Any choice indicating loss of sensation is INCORRECT. - Salk vs. Sabin Antibody Induction:
- Trap: Questions asking which vaccine prevents intestinal replication/shedding of poliovirus.
- Fact: Only Sabin (OPV) produces secretory IgA in the gut. Patients receiving Salk (IPV) can still replicate and shed wild-type virus in their stool upon exposure. - Herpangina vs. Herpes Simplex Stomatitis:
- Trap: Identifying the rash site for Herpangina.
- Fact: Herpangina (Coxsackie A) presents with vesicles confined to the posterior pharynx, tonsils, and tongue (not anterior labial lips). - Pleurodynia Misdiagnosis in Children:
- Trap: A child presenting with fever and acute abdominal pain after malaise.
- Fact: This is a classic presentation for Coxsackie B Pleurodynia (Epidemic Myalgia), where abdominal pain occurs in ~50% of pediatric cases. - Myocarditis Presentation:
- Trap: Case presenting with chest pain mimicking myocardial infarction/IHD.
- Fact: Look for the presence of fever and young age to distinguish Coxsackie B myocarditis from ischemic heart disease.
📝 Quick Review Checklist
I can state the genomic structure and family of Enteroviruses (+ssRNA, naked, icosahedral, Picornaviridae).
I understand the pathogenesis of enteroviral infection from mucosal entry to secondary viremia.
I can list the four clinical outcomes of poliovirus infection (Mild, Non-paralytic, Paralytic, Post-polio atrophy).
I know that paralytic polio causes lower motor neuron damage with no sensory loss.
I can differentiate between Group A (skin/mucous membranes) and Group B (heart/pleura/pancreas/liver) Coxsackieviruses.
I can describe the clinical features of Herpangina, Hand-Foot-Mouth disease, and Pleurodynia.
I know that Coxsackie Group B is the primary viral cause of myocarditis and pericarditis.
I can contrast the immunological outcomes of the Salk (IPV) vs. Sabin (OPV) polio vaccines regarding mucosal IgA.
I can identify the diagnostic tests used for enteroviruses (RT-PCR, primary kidney cell cultures, serology).